These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 7749306)

  • 21. Rare Streptomyces N-formyl amino-salicylamides inhibit oncogenic K-Ras.
    Salim AA; Cho KJ; Tan L; Quezada M; Lacey E; Hancock JF; Capon RJ
    Org Lett; 2014 Oct; 16(19):5036-9. PubMed ID: 25238489
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Reversion of v-H-ras-transformed NIH 3T3 cells by apigenin through inhibiting mitogen activated protein kinase and its downstream oncogenes.
    Kuo ML; Yang NC
    Biochem Biophys Res Commun; 1995 Jul; 212(3):767-75. PubMed ID: 7626110
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The ras oncogene-mediated sensitization of human cells to topoisomerase II inhibitor-induced apoptosis.
    Koo HM; Gray-Goodrich M; Kohlhagen G; McWilliams MJ; Jeffers M; Vaigro-Wolff A; Alvord WG; Monks A; Paull KD; Pommier Y; Vande Woude GF
    J Natl Cancer Inst; 1999 Feb; 91(3):236-44. PubMed ID: 10037101
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Oncogene-blocking therapies: new insights from conditional mouse tumor models.
    Hengstler JG; Bockamp EO; Hermes M; Brulport M; Bauer A; Schormann W; Schiffer IB; Hausherr C; Eshkind L; Antunes C; Franzen A; Krishnamurthi K; Lausch E; Lessig R; Chakrabarti T; Prawitt D; Zabel B; Spangenberg C
    Curr Cancer Drug Targets; 2006 Nov; 6(7):603-12. PubMed ID: 17100566
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [EGFR pathway and mechanism of action of tyrosine kinase inhibitors].
    Zalcman G
    Rev Pneumol Clin; 2007 Jan; 63(1 Pt 2):2S5-6. PubMed ID: 17242635
    [No Abstract]   [Full Text] [Related]  

  • 26. Oncogene expression and cytotoxic activity of tumor necrosis factor against human cancer cells.
    Dhingra K; Gooding LR; Gordon DS
    J Biol Response Mod; 1989 Aug; 8(4):337-43. PubMed ID: 2666584
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diversifying microbial natural products for drug discovery.
    Knight V; Sanglier JJ; DiTullio D; Braccili S; Bonner P; Waters J; Hughes D; Zhang L
    Appl Microbiol Biotechnol; 2003 Oct; 62(5-6):446-58. PubMed ID: 12838377
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mitogen-activated protein kinase activation resulting from selective oncogene expression in NIH 3T3 and rat 1a cells.
    Gallego C; Gupta SK; Heasley LE; Qian NX; Johnson GL
    Proc Natl Acad Sci U S A; 1992 Aug; 89(16):7355-9. PubMed ID: 1323832
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A new antibiotic, structurally related to leptomycin A, flattens the morphology of v-ras(ts) NRK cells.
    Hosokawa N; Iinuma H; Naganawa H; Hamada M; Takeuchi T; Itoh T; Hori M
    J Antibiot (Tokyo); 1993 Apr; 46(4):676-8. PubMed ID: 8501010
    [No Abstract]   [Full Text] [Related]  

  • 30. Activation of phosphatidylcholine-specific phospholipase C in cell growth and oncogene transformation.
    Moscat J; Cornet ME; Diaz-Meco MT; Larrodera P; Lopez-Alanon D; Lopez-Barahona M
    Biochem Soc Trans; 1989 Dec; 17(6):988-91. PubMed ID: 2560749
    [No Abstract]   [Full Text] [Related]  

  • 31. Synergistic effect of the v-myc oncogene with H-ras on radioresistance.
    McKenna WG; Weiss MC; Endlich B; Ling CC; Bakanauskas VJ; Kelsten ML; Muschel RJ
    Cancer Res; 1990 Jan; 50(1):97-102. PubMed ID: 2403420
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Isolation and purification of secondary metabolites.
    McAlpine JB; Hochlowski JE
    Biotechnology; 1994; 26():349-87. PubMed ID: 7749312
    [No Abstract]   [Full Text] [Related]  

  • 33. Oncogene alterations in rat colon tumors induced by N-methyl-N-nitrosourea.
    Alexander RJ; Buxbaum JN; Raicht RF
    Am J Med Sci; 1992 Jan; 303(1):16-24. PubMed ID: 1728873
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oncogene signal transduction inhibitors from medicinal plants.
    Chang CJ; Ashendel CL; Geahlen RL; McLaughlin JL; Waters DJ
    In Vivo; 1996; 10(2):185-90. PubMed ID: 8744799
    [TBL] [Abstract][Full Text] [Related]  

  • 35. 10'-Desmethoxystreptonigrin, a novel analog of streptonigrin.
    Liu WC; Barbacid M; Bulgar M; Clark JM; Crosswell AR; Dean L; Doyle TW; Fernandes PB; Huang S; Manne V
    J Antibiot (Tokyo); 1992 Apr; 45(4):454-7. PubMed ID: 1592677
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Non-receptor tyrosine kinase inhibitors in lung cancer.
    Hahn O; Salgia R
    Anticancer Agents Med Chem; 2007 Nov; 7(6):633-42. PubMed ID: 18045058
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The bcr-c-abl tyrosine kinase activity is extinguished by TPA in K562 leukemia cells.
    Alitalo R
    FEBS Lett; 1987 Oct; 222(2):293-8. PubMed ID: 3477472
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lipid signalling pathways in normal and ras-transfected NIH/3T3 cells.
    Matyas GR; Fishman PH
    Cell Signal; 1989; 1(4):395-404. PubMed ID: 2561989
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Oncogenes and tumor suppressor genes in the signal transduction pathways of growth factors].
    Buday L
    Orv Hetil; 1994 Nov; 135(47):2579-84. PubMed ID: 7824256
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Inhibitors of growth factor functions, possible antineoplastic agents].
    Umezaza K; Toi M
    Tanpakushitsu Kakusan Koso; 1991 May; 36(7):1429-35. PubMed ID: 1871364
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.